Brazilian experience using high dose sequential followed by autologous hematopoietic stem cell transplantation for malignant lymphomas

The therapeutic of malignant lymphomas has undergone several advances through the last decades. Despite these advances, the management of relapsed and resistant patients with malignant lymphomas using conventional chemotherapy is disappointing. While patients with Hodgkin’s lymphoma (HL) have a favorable outcome when treated with regimens such as ABVD, MOPPABV and BEACOPP, with complete remission (CR) rates as high as 95%, and cure rates of 60- 85%.1,2 Some patients with advanced disease and poor prognostic factors have a poor outcome, with disease free survival (DFS) of about 10%.3-5